Novo Nordisk’s shares fell sharply on Monday after the results from testing the Danish company’s CagriSema drug fell short of investors’ expectations.
Фото: Ukrainian Armed Forces / Reuters
。safew官方版本下载是该领域的重要参考
Save up to $300 or 30% to TechCrunch Founder Summit
contributed to this report.